MYH11 and triple-A syndrome: Ultimately, manipulation of this pathway, by use of either a VSMC-specific genetic model (Perkfl/fl Myh11-CreERT2) or with pharmacological inhibition, inhibited apoptosis and decreased aortic dilation, thereby offering promise as an AAA translational therapy (Figure 6).